Stephen Roberts Walsh, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
AIDS Vaccines | 19 | 2024 | 896 | 3.270 |
Why?
|
HIV Antibodies | 17 | 2024 | 1302 | 1.850 |
Why?
|
HIV-1 | 22 | 2024 | 6858 | 1.410 |
Why?
|
Antibodies, Neutralizing | 19 | 2024 | 1936 | 1.380 |
Why?
|
Vaccinia virus | 8 | 2023 | 329 | 1.280 |
Why?
|
Smallpox Vaccine | 5 | 2013 | 77 | 1.260 |
Why?
|
HIV Infections | 22 | 2024 | 17342 | 0.830 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 6 | 2024 | 369 | 0.750 |
Why?
|
Immunization, Passive | 1 | 2021 | 616 | 0.640 |
Why?
|
Orthopoxvirus | 1 | 2012 | 11 | 0.420 |
Why?
|
Vaccinia | 1 | 2013 | 70 | 0.420 |
Why?
|
Immunization, Secondary | 3 | 2024 | 368 | 0.400 |
Why?
|
Antibodies, Viral | 10 | 2024 | 3149 | 0.400 |
Why?
|
Poxviridae Infections | 1 | 2011 | 11 | 0.390 |
Why?
|
Adenoviruses, Human | 4 | 2014 | 255 | 0.390 |
Why?
|
Vaccines, Combined | 4 | 2023 | 70 | 0.360 |
Why?
|
Vaccination | 7 | 2023 | 3370 | 0.360 |
Why?
|
Genetic Vectors | 7 | 2023 | 3392 | 0.360 |
Why?
|
Meningococcal Vaccines | 2 | 2023 | 94 | 0.360 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2015 | 825 | 0.350 |
Why?
|
Double-Blind Method | 17 | 2023 | 12333 | 0.320 |
Why?
|
Injections, Intramuscular | 5 | 2024 | 555 | 0.310 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 7995 | 0.310 |
Why?
|
Vaccines, Synthetic | 7 | 2024 | 612 | 0.290 |
Why?
|
Antibodies, Monoclonal | 4 | 2022 | 9171 | 0.270 |
Why?
|
Immunization Schedule | 4 | 2020 | 227 | 0.240 |
Why?
|
Vaccines | 2 | 2023 | 838 | 0.230 |
Why?
|
Vaccines, DNA | 2 | 2023 | 283 | 0.230 |
Why?
|
Clindamycin | 1 | 2004 | 139 | 0.230 |
Why?
|
Uremia | 1 | 2005 | 202 | 0.220 |
Why?
|
Fasciitis, Necrotizing | 1 | 2004 | 79 | 0.220 |
Why?
|
Viral Vaccines | 2 | 2020 | 595 | 0.220 |
Why?
|
Immunity, Cellular | 5 | 2023 | 1550 | 0.220 |
Why?
|
Meningococcal Infections | 1 | 2023 | 77 | 0.210 |
Why?
|
Herpesviridae | 1 | 2003 | 104 | 0.200 |
Why?
|
Young Adult | 20 | 2024 | 59191 | 0.200 |
Why?
|
Streptococcus pyogenes | 1 | 2004 | 292 | 0.190 |
Why?
|
Gene Products, env | 2 | 2012 | 250 | 0.190 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2018 | 5671 | 0.190 |
Why?
|
Adjuvants, Immunologic | 3 | 2022 | 990 | 0.190 |
Why?
|
Nasopharynx | 1 | 2024 | 400 | 0.190 |
Why?
|
Lymphopenia | 1 | 2023 | 281 | 0.190 |
Why?
|
Adult | 31 | 2024 | 220995 | 0.170 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.170 |
Why?
|
Chloroquine | 1 | 2021 | 275 | 0.170 |
Why?
|
Vaccines, Inactivated | 1 | 2020 | 178 | 0.170 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2021 | 445 | 0.170 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10175 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2012 | 4570 | 0.160 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2021 | 280 | 0.160 |
Why?
|
HIV Seropositivity | 2 | 2022 | 959 | 0.160 |
Why?
|
HIV Antigens | 2 | 2020 | 325 | 0.160 |
Why?
|
Genome, Viral | 1 | 2003 | 665 | 0.160 |
Why?
|
Neurophysiology | 1 | 2020 | 144 | 0.160 |
Why?
|
Macaca mulatta | 2 | 2020 | 2328 | 0.160 |
Why?
|
Primates | 1 | 2021 | 521 | 0.160 |
Why?
|
Antiviral Agents | 4 | 2022 | 3037 | 0.150 |
Why?
|
Humans | 54 | 2024 | 760740 | 0.150 |
Why?
|
Immunocompromised Host | 2 | 2014 | 858 | 0.150 |
Why?
|
Receptors, Virus | 1 | 2021 | 639 | 0.150 |
Why?
|
Dose-Response Relationship, Immunologic | 3 | 2013 | 359 | 0.150 |
Why?
|
Viral Load | 2 | 2024 | 3325 | 0.150 |
Why?
|
Middle Aged | 24 | 2024 | 220603 | 0.140 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6305 | 0.140 |
Why?
|
Drug Carriers | 3 | 2018 | 706 | 0.140 |
Why?
|
Hydroxychloroquine | 1 | 2021 | 426 | 0.140 |
Why?
|
Female | 34 | 2024 | 392203 | 0.140 |
Why?
|
Drug Resistance, Bacterial | 1 | 2004 | 1049 | 0.140 |
Why?
|
Vaccines, Attenuated | 3 | 2013 | 315 | 0.140 |
Why?
|
Skin Diseases | 1 | 2005 | 1094 | 0.130 |
Why?
|
Male | 31 | 2024 | 360402 | 0.130 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 3798 | 0.130 |
Why?
|
HIV | 1 | 2003 | 1580 | 0.130 |
Why?
|
Epidemics | 1 | 2021 | 512 | 0.130 |
Why?
|
Adolescent | 11 | 2024 | 88247 | 0.120 |
Why?
|
Immunologic Memory | 1 | 2021 | 1355 | 0.120 |
Why?
|
Models, Animal | 1 | 2021 | 2108 | 0.120 |
Why?
|
Adenoviridae | 2 | 2016 | 1084 | 0.120 |
Why?
|
Gene Expression | 2 | 2020 | 7569 | 0.120 |
Why?
|
B-Lymphocytes | 2 | 2024 | 4745 | 0.110 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2021 | 4365 | 0.110 |
Why?
|
Paramyxoviridae Infections | 1 | 2014 | 57 | 0.110 |
Why?
|
Fowlpox virus | 1 | 2012 | 21 | 0.110 |
Why?
|
Exercise Therapy | 1 | 2020 | 929 | 0.100 |
Why?
|
Kidney Failure, Chronic | 1 | 2005 | 2474 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1896 | 0.100 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4533 | 0.100 |
Why?
|
Forecasting | 1 | 2021 | 2924 | 0.100 |
Why?
|
Patient Selection | 1 | 2024 | 4237 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2003 | 2722 | 0.100 |
Why?
|
Immunity, Humoral | 3 | 2024 | 600 | 0.090 |
Why?
|
Boston | 1 | 2024 | 9313 | 0.090 |
Why?
|
Low Back Pain | 1 | 2020 | 982 | 0.090 |
Why?
|
Immunity, Mucosal | 1 | 2014 | 483 | 0.090 |
Why?
|
Capsid Proteins | 1 | 2014 | 464 | 0.090 |
Why?
|
Placebos | 3 | 2021 | 1667 | 0.080 |
Why?
|
Cyclooxygenase 2 | 1 | 2011 | 596 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2149 | 0.080 |
Why?
|
Antigens, Viral | 1 | 2013 | 988 | 0.080 |
Why?
|
Recombinant Proteins | 2 | 2022 | 6520 | 0.080 |
Why?
|
Antibody Formation | 3 | 2020 | 1390 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3730 | 0.060 |
Why?
|
Pneumonia, Staphylococcal | 1 | 2005 | 39 | 0.060 |
Why?
|
Chronic Disease | 1 | 2020 | 9310 | 0.060 |
Why?
|
Intestinal Mucosa | 2 | 2014 | 3031 | 0.060 |
Why?
|
Meningitis, Viral | 1 | 2004 | 50 | 0.060 |
Why?
|
Meningitis, Aseptic | 1 | 2004 | 59 | 0.060 |
Why?
|
Retrospective Studies | 2 | 2024 | 80583 | 0.060 |
Why?
|
Cancer Vaccines | 1 | 2011 | 1037 | 0.060 |
Why?
|
Treatment Outcome | 7 | 2020 | 64572 | 0.050 |
Why?
|
Animals | 7 | 2023 | 168202 | 0.050 |
Why?
|
Exercise | 1 | 2020 | 5886 | 0.050 |
Why?
|
Herpesvirus 2, Human | 1 | 2004 | 191 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1348 | 0.050 |
Why?
|
Pregnancy | 2 | 2021 | 29869 | 0.050 |
Why?
|
Neoplasms | 1 | 2011 | 22131 | 0.050 |
Why?
|
HIV Envelope Protein gp41 | 1 | 2024 | 303 | 0.050 |
Why?
|
Virus Replication | 2 | 2003 | 2427 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 3 | 2014 | 1834 | 0.050 |
Why?
|
Vaccines, Conjugate | 1 | 2023 | 328 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10203 | 0.050 |
Why?
|
Graft vs Host Disease | 1 | 2014 | 3026 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4172 | 0.050 |
Why?
|
Herpes Simplex | 1 | 2004 | 465 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2023 | 629 | 0.050 |
Why?
|
Interferon-gamma | 1 | 2009 | 3145 | 0.050 |
Why?
|
Injections, Intradermal | 2 | 2010 | 116 | 0.040 |
Why?
|
Liposomes | 1 | 2024 | 784 | 0.040 |
Why?
|
Diabetic Foot | 1 | 2004 | 379 | 0.040 |
Why?
|
Fatal Outcome | 1 | 2005 | 1835 | 0.040 |
Why?
|
Cell Line | 2 | 2013 | 15577 | 0.040 |
Why?
|
Lactation | 1 | 2022 | 397 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 857 | 0.040 |
Why?
|
Viremia | 1 | 2022 | 706 | 0.040 |
Why?
|
Peru | 1 | 2021 | 890 | 0.040 |
Why?
|
Poland Syndrome | 1 | 1997 | 14 | 0.040 |
Why?
|
Dextrocardia | 1 | 1997 | 37 | 0.040 |
Why?
|
Vaccines, Subunit | 1 | 2018 | 158 | 0.040 |
Why?
|
Microbial Sensitivity Tests | 1 | 2004 | 1936 | 0.040 |
Why?
|
Sepsis | 1 | 2011 | 2585 | 0.040 |
Why?
|
Antibodies, Bacterial | 1 | 2023 | 1464 | 0.040 |
Why?
|
HIV Envelope Protein gp120 | 1 | 2021 | 914 | 0.040 |
Why?
|
DNA | 2 | 2021 | 7196 | 0.040 |
Why?
|
Orthoreovirus | 1 | 1996 | 22 | 0.030 |
Why?
|
Africa, Eastern | 1 | 2016 | 76 | 0.030 |
Why?
|
Giant Cells | 1 | 1996 | 188 | 0.030 |
Why?
|
Pneumonia, Viral | 1 | 2014 | 3209 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 4569 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 994 | 0.030 |
Why?
|
Placebo Effect | 1 | 2019 | 518 | 0.030 |
Why?
|
Epitopes | 1 | 2021 | 2501 | 0.030 |
Why?
|
Cell Lineage | 1 | 2024 | 2553 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15829 | 0.030 |
Why?
|
Plasmids | 1 | 2020 | 2265 | 0.030 |
Why?
|
International Cooperation | 1 | 2021 | 1422 | 0.030 |
Why?
|
Aged | 6 | 2024 | 169092 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2014 | 123 | 0.030 |
Why?
|
United States | 4 | 2024 | 72292 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3117 | 0.030 |
Why?
|
Wound Healing | 1 | 2004 | 2802 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8652 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2021 | 1894 | 0.030 |
Why?
|
Patient Participation | 1 | 2021 | 1443 | 0.020 |
Why?
|
Skin | 1 | 2005 | 4472 | 0.020 |
Why?
|
Caco-2 Cells | 1 | 2011 | 363 | 0.020 |
Why?
|
South Africa | 1 | 2016 | 1843 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39062 | 0.020 |
Why?
|
Cell Membrane Permeability | 1 | 2011 | 574 | 0.020 |
Why?
|
Virus Shedding | 1 | 2010 | 109 | 0.020 |
Why?
|
Peritonitis | 1 | 2011 | 368 | 0.020 |
Why?
|
Ileum | 1 | 2011 | 557 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8516 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1562 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2021 | 5109 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9644 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 671 | 0.020 |
Why?
|
Sex Factors | 1 | 2021 | 10549 | 0.020 |
Why?
|
Immunotherapy | 1 | 2003 | 4642 | 0.020 |
Why?
|
Sirolimus | 1 | 2014 | 1533 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10507 | 0.020 |
Why?
|
Colon | 1 | 2014 | 1791 | 0.020 |
Why?
|
Respiratory Insufficiency | 1 | 2014 | 1230 | 0.020 |
Why?
|
Hypertension | 1 | 2005 | 8532 | 0.020 |
Why?
|
Age Factors | 1 | 2021 | 18381 | 0.010 |
Why?
|
Bacteremia | 1 | 2011 | 977 | 0.010 |
Why?
|
Time Factors | 2 | 2020 | 39908 | 0.010 |
Why?
|
Risk Assessment | 1 | 2004 | 23974 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 6188 | 0.010 |
Why?
|
Respiration, Artificial | 1 | 2014 | 2630 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14599 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 30015 | 0.010 |
Why?
|
Cytokines | 1 | 2014 | 7373 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41464 | 0.010 |
Why?
|
Prospective Studies | 1 | 2023 | 54364 | 0.010 |
Why?
|
DNA, Viral | 1 | 2004 | 2194 | 0.010 |
Why?
|
Brefeldin A | 1 | 1996 | 68 | 0.010 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 1996 | 151 | 0.010 |
Why?
|
Tunicamycin | 1 | 1996 | 108 | 0.010 |
Why?
|
Protein Synthesis Inhibitors | 1 | 1996 | 189 | 0.010 |
Why?
|
Cyclopentanes | 1 | 1996 | 87 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 58919 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 14388 | 0.010 |
Why?
|
Deoxyglucose | 1 | 1996 | 333 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 22117 | 0.010 |
Why?
|
Child | 1 | 2021 | 80089 | 0.010 |
Why?
|
Biological Transport | 1 | 1996 | 2089 | 0.010 |
Why?
|
Recurrence | 1 | 2004 | 8426 | 0.010 |
Why?
|
Viral Proteins | 1 | 1996 | 1799 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1996 | 6126 | 0.000 |
Why?
|
Mice | 2 | 2011 | 81368 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1997 | 26183 | 0.000 |
Why?
|